Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287745 | 0.88 | ALDH1A1 (0.51) | DRD2MAPTPIM1PIM3PIM2 | |
| SCHEMBL4287750 | 0.88 | ALDH1A1 (0.51) | DRD2MAPTPIM1PIM3PIM2 | |
| SCHEMBL5232224 | 0.88 | ALDH1A1 (0.51) | DRD2MAPTPIM1PIM3PIM2 | |
| SCHEMBL12836001 | 0.86 | LMNA (0.54) | DRD2MAPTPIM1PIM3PIM2 | |
| SCHEMBL7852754 | 0.85 | ALDH1A1 (0.48) | DRD2MAPTPIM1PIM3PIM2 | |
| SCHEMBL7852751 | 0.85 | ALDH1A1 (0.48) | DRD2MAPTPIM1PIM3PIM2 | |
| SCHEMBL4367577 | 0.84 | TDP1 (0.48) | MAPTHTTALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1027561 | 0.84 | TDP1 (0.48) | MAPTHTTALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL13419583 | 0.83 | ALDH1A1 (0.58) | DRD2MAPTSUV39H2HTTALDH1A1 | |
| SCHEMBL30781309 | 0.83 | PIM1 (0.49) | DRD2PIM1PIM3PIM2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | DRD2 4537/4885MAPT 3239/4885PIM1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.